First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Takuma Miura et al.|Clinical Cancer Research|2021Cited by 97
Initial intravenous immunoglobulin therapy without aspirin for acute Kawasaki disease: a retrospective cohort study with a Bayesian inferenceKen Hayashi, Etsuko Tsuda, Masaru Yamakawa et al.|BMJ Paediatrics Open|2024Cited by 9